Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

sults, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

  • our ability to borrow additional amounts under the loan agreement, which is subject to the discretion of the Lender;
  • our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan by the September 14, 2009 maturity date;
  • our ability to control our operating expenses;
  • our failure to timely recruit and enroll patients for the FDG-PET clinical trial, as well as any future clinical trial;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays;

  • '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... , June 1, 2015 /CNW/ - Resverlogix Corp. (TSX: ... RVX-208 was presented at the ERA-EDTA Congress in ... "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key ... and Chronic Kidney Disease (CKD); a Post-hoc Analysis of ... Dr. Kam Kalantar-Zadeh , Professor ...
(Date:6/1/2015)... June 1, 2015   Epic Sciences, Inc. , ... and offerings to personalize and advance the treatment and ... the available credit under its existing credit facility with ... increases the available capacity of the facility from $5 ... by 27 months to April 1, 2019.  The availability ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Researchers have completed the first thorough, system-level assessment ... of microbes known as Shewanella. Microbes belonging to ... and cleaning up contaminated areas in the environment. ... Institute of Technology, Michigan State University and the ...
... ... , ... The Honolulu-based Pacific Health Research Institute (PHRI) has received $2.8 million in research funding ... a major lung cancer screening study in Hawaii, for two more years. , , , ...
... , , BOTHELL, Wash., ... a leading developer, manufacturer, and marketer of biopreservation tools for ... BloodStor biopreservation media product platform. The product family includes ... as well as other variants for peripheral blood derived stem ...
Cached Biology Technology:Hidden diversity in key environmental cleanup microbes found by systems biology assessment 2Hidden diversity in key environmental cleanup microbes found by systems biology assessment 3Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 2BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 3
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... discovered that iron-containing nanoparticles being tested for use in ... and interfere with the formation of their signal-transmitting extensions. ... and most life forms and iron oxide nanoparticles were ... professor of materials science at UCSD and senior author ...
... box glowing with fluorescent light, Stacie Grassano pulls out a tube. ... up to her face. Inside, a tree branch is speckled with ... Scott Costa. , Costa brings the branch close to his eye. ... success story." , For some, a fungus success story means ...
... announced that it has added high-density genotyping on ... list of services. Stan Nelson, the principal investigator ... for its user-base of ~10,000 investigators across the ... of the scientific community." , The Consortium ...
Cached Biology News:Widely used iron nanoparticles exhibit toxic effects on neuronal cells 2Widely used iron nanoparticles exhibit toxic effects on neuronal cells 3Fungal factories may save hemlock forests 2Fungal factories may save hemlock forests 3NIH neuroscience microarray consortium launches high-throughput genotyping services 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Request Info...
...
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
Biology Products: